Skip to main content

Advertisement

SpringerLink
Log in

Increased expression of stomatin-like protein 2 (STOML2) predicts decreased survival in gastric adenocarcinoma: a retrospective study

  • Original Paper
  • Published:
Medical Oncology Aims and scope Submit manuscript

Abstract

Stomatin-like protein 2 (STOML2), a member of the stomatin, has been reported to be upregulated in several human cancers. However, its role and clinical significance in gastric adenocarcinoma remains unclear to date. The purpose of this retrospective study was to explore whether there was a correlation between the expression of STOML2 by immunohistochemistry and the clinical outcome of a large group of patients with gastric adenocarcinoma. In this retrospective study, we performed immunohistochemistry to evaluation of STOML2 expression in a large panel of gastric adenocarcinoma samples. The receiver operating characteristic method was used to define the STOML2 immunoreactivity score cutoff value. The clinical/prognostic significance of STOML2 expression was analyzed statistically. Kaplan–Meier analysis was used to compare the postoperative survival between groups. STOML2 was overexpressed in gastric cancer compared with paracancerous normal mucosa. Increased STOML2 expression was associated with higher histologic grade (P = 0.047), T category (P < 0.001), and N category (P = 0.01). Patients with high expression of STOML2 demonstrated shortened overall survival compared with those with low expression of STOML2 (median of 38.9 vs. 64.0 months, P < 0.001). Furthermore, STOML2 expression could stratify patients survival in stage N0 (P < 0.001). Multivariate analysis showed that the level of STOML2 expression was an independent prognostic factor in gastric adenocarcinoma (RR = 1.920, P = 0.001). Increased expression of STOML2 suggests unfavorable prognosis for gastric adenocarcinoma patients. Further studies are warranted.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin. 2013;63:11–30.

    Article  PubMed  Google Scholar 

  2. Macdonald JS, Smalley SR, Benedetti J, et al. Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. New Engl J Med. 2001;345:725–30.

    Article  CAS  PubMed  Google Scholar 

  3. Tamura Y, Higashi M, Kitamoto S, et al. MUC4 and MUC1 expression in adenocarcinoma of the stomach correlates with vessel invasion and lymph node metastasis: an immunohistochemical study of early gastric cancer. PLoS ONE. 2012;7:e49251.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  4. Mrena J, Wiksten JP, Kokkola A, Nordling S, Ristimaki A, Haglund C. COX-2 is associated with proliferation and apoptosis markers and serves as an independent prognostic factor in gastric cancer. Tumour Biol. 2010;31:1–7.

    Article  CAS  PubMed  Google Scholar 

  5. Gulubova M, Manolova I, Kyurkchiev D, Julianov A, Altunkova I. Decrease in intrahepatic CD56 + lymphocytes in gastric and colorectal cancer patients with liver metastases. APMIS. 2009;117:870–9.

    Article  PubMed  Google Scholar 

  6. Iwasa S, Yanagawa T, Fan J, Katoh R. Expression of CXCR4 and its ligand SDF-1 in intestinal-type gastric cancer is associated with lymph node and liver metastasis. Anticancer Res. 2009;29:4751–8.

    PubMed  Google Scholar 

  7. Wang K, Kan J, Yuen ST, et al. Exome sequencing identifies frequent mutation of ARID1A in molecular subtypes of gastric cancer. Nat Genet. 2011;43:1219–23.

    Article  CAS  PubMed  Google Scholar 

  8. Song IS, Ha GH, Kim JM, et al. Human ZNF312b oncogene is regulated by Sp1 binding to its promoter region through DNA demethylation and histone acetylation in gastric cancer. Int J Cancer. 2011;129:2124–33.

    Article  CAS  PubMed  Google Scholar 

  9. Shah MA, Khanin R, Tang L, et al. Molecular classification of gastric cancer: a new paradigm. Clin Cancer Res. 2011;17:2693–701.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  10. Green JB, Young JP. Slipins: ancient origin, duplication and diversification of the stomatin protein family. BMC Evol Biol. 2008;8:44.

    Article  PubMed Central  PubMed  Google Scholar 

  11. Wang Y, Morrow JS. Identification and characterization of human SLP-2, a novel homologue of stomatin (band 7.2b) present in erythrocytes and other tissues. J Biol Chem. 2000;275:8062–71.

    Article  CAS  PubMed  Google Scholar 

  12. Zhang L, Ding F, Cao W, et al. Stomatin-like protein 2 is overexpressed in cancer and involved in regulating cell growth and cell adhesion in human esophageal squamous cell carcinoma. Clin Cancer Res. 2006;12:1639–46.

    Article  CAS  PubMed  Google Scholar 

  13. Cao WF, Zhang LY, Liu MB, Tang PZ, Liu ZH, Sun BC. Prognostic significance of stomatin-like protein 2 overexpression in laryngeal squamous cell carcinoma: clinical, histologic, and immunohistochemistry analyses with tissue microarray. Hum Pathol. 2007;38:747–52.

    Article  CAS  PubMed  Google Scholar 

  14. Song L, Liu L, Wu Z, et al. Knockdown of stomatin-like protein 2 (STOML2) reduces the invasive ability of glioma cells through inhibition of the NF-kappaB/MMP-9 pathway. J Pathol. 2012;226:534–43.

    Article  CAS  PubMed  Google Scholar 

  15. Chang D, Ma K, Gong M, et al. SLP-2 overexpression is associated with tumour distant metastasis and poor prognosis in pulmonary squamous cell carcinoma. Biomarkers. 2010;15:104–10.

    Article  CAS  PubMed  Google Scholar 

  16. Cao W, Zhang B, Liu Y, et al. High-level SLP-2 expression and HER-2/neu protein expression are associated with decreased breast cancer patient survival. Am J Clin Pathol. 2007;128:430–6.

    Article  CAS  PubMed  Google Scholar 

  17. Cui Z, Zhang L, Hua Z, Cao W, Feng W, Liu Z. Stomatin-like protein 2 is overexpressed and related to cell growth in human endometrial adenocarcinoma. Oncol Rep. 2007;17:829–33.

    CAS  PubMed  Google Scholar 

  18. Wang Y, Cao W, Yu Z, Liu Z. Downregulation of a mitochondria associated protein SLP-2 inhibits tumor cell motility, proliferation and enhances cell sensitivity to chemotherapeutic reagents. Cancer Biol Ther. 2009;8:1651–8.

    Article  CAS  PubMed  Google Scholar 

  19. Taylor SW, Fahy E, Zhang B, et al. Characterization of the human heart mitochondrial proteome. Nat Biotechnol. 2003;21:281–6.

    Article  CAS  PubMed  Google Scholar 

  20. Deryugina EI, Quigley JP. Matrix metalloproteinases and tumor metastasis. Cancer Metastasis Rev. 2006;25:9–34.

    Article  CAS  PubMed  Google Scholar 

  21. Turpeenniemi-Hujanen T. Gelatinases (MMP-2 and -9) and their natural inhibitors as prognostic indicators in solid cancers. Biochimie. 2005;87:287–97.

    Article  CAS  PubMed  Google Scholar 

  22. Louis DN, Pomeroy SL, Cairncross JG. Focus on central nervous system neoplasia. Cancer Cell. 2002;1:125–8.

    Article  CAS  PubMed  Google Scholar 

  23. Chintala SK, Tonn JC, Rao JS. Matrix metalloproteinases and their biological function in human gliomas. Int J Dev Neurosci. 1999;17:495–502.

    Article  CAS  PubMed  Google Scholar 

  24. Chen LF, Greene WC. Shaping the nuclear action of NF-kappaB. Nat Rev Mol Cell Biol. 2004;5:392–401.

    Article  CAS  PubMed  Google Scholar 

  25. Naugler WE, Karin M. NF-kappaB and cancer-identifying targets and mechanisms. Curr Opin Genet Dev. 2008;18:19–26.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  26. Perkins ND. Integrating cell-signalling pathways with NF-kappaB and IKK function. Nat Rev Mol Cell Biol. 2007;8:49–62.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgments

This work was worked supported by the National Natural Science Foundation of China (Nos. 81172565 and 81202135).

Conflict of interest

The authors declare that they have no conflict of interest.

Author information

Authors and Affiliations

  1. Department of Medical Oncology, The First Affiliated Hospital of Xiamen University, 55 Zhenhai Road, Xiamen, 361000, Fujian, People’s Republic of China

    Xiao-Hong Li

  2. Department of Forensic Medicine, Zhongshan School of Medicine, Sun Yat-sen University, Guangzhou City, 510080, Guangdong Province, People’s Republic of China

    Fan He

  3. Department of Gastric and Pancreatic Surgery, Sun Yat-sen University Cancer Center, Collaborative Innovation Center for Cancer Medicine, No. 651, Dongfeng East Road, Guangzhou City, 510060, Guangdong Province, People’s Republic of China

    Chun-Yu Huang & Zhi-Wei Zhou

  4. State Key Laboratory of Oncology in South China, Guangzhou City, Guangdong Province, People’s Republic of China

    Chun-Yu Huang & Zhi-Wei Zhou

  5. Department of Pathology, Sun Yat-sen University Cancer Center, Guangzhou City, Guangdong Province, People’s Republic of China

    Shu-Mei Yan, Yong Li & Yun Cao

Authors
  1. Xiao-Hong Li
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Fan He
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Shu-Mei Yan
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Yong Li
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Yun Cao
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Chun-Yu Huang
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Zhi-Wei Zhou
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding authors

Correspondence to Chun-Yu Huang or Zhi-Wei Zhou.

Additional information

Xiao-Hong Li and Fan He have contributed equally to this work and share the first authorship.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Li, XH., He, F., Yan, SM. et al. Increased expression of stomatin-like protein 2 (STOML2) predicts decreased survival in gastric adenocarcinoma: a retrospective study. Med Oncol 31, 763 (2014). https://doi.org/10.1007/s12032-013-0763-9

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1007/s12032-013-0763-9

Keywords

Search

Navigation